Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellie M Carrell

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Current Opinion in Genetics & Development|April 5, 2017
Myotonic dystrophy: approach to therapyCharles A Thornton, Eric Wang, Ellie M Carrell
Annals of Neurology|August 29, 2025
Co-Opting MBNL-Dependent Alternative Splicing Cassette Exons to Control Gene Therapy in Myotonic DystrophySamuel T Carrell, Ellie M Carrell, Ryan Giovenco, et al.
Molecular Therapy. Methods & Clinical Development|May 16, 2022
Combined overexpression of ATXN1L and mutant ATXN1 knockdown by AAV rescue motor phenotypes and gene signatures in SCA1 miceEllie M Carrell, Megan S Keiser, Ashley B Robbins, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 3, 2016
Orai1 enhances muscle endurance by promoting fatigue-resistant type I fiber content but not through acute store-operated Ca2+ entryEllie M Carrell, Aundrea R Coppola, Helen J McBride, et al.
Nature Communications|November 19, 2013
Orai1-dependent calcium entry promotes skeletal muscle growth and limits fatigueLan Wei-Lapierre, Ellie M Carrell, Simona Boncompagni, et al.
Molecular Therapy. Nucleic Acids|September 24, 2024
Cas9 editing of <i>ATXN1</i> in a spinocerebellar ataxia type 1 mice and human iPSC-derived neuronsKelly J Fagan, Guillem Chillon, Ellie M Carrell, et al.
Molecular Therapy. Nucleic Acids|July 9, 2024
Temporal restriction of Cas9 expression improves CRISPR-mediated deletion efficacy and fidelityJesse A Weber, Jonathan F Lang, Ellie M Carrell, et al.
Plos One|November 16, 2012
Allele-specific gene silencing in two mouse models of autosomal dominant skeletal myopathyRyan E Loy, John D Lueck, Mohammed A Mostajo-Radji, et al.
Human Molecular Genetics|August 15, 2016
Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in miceSamuel T Carrell, Ellie M Carrell, David Auerbach, et al.
Molecular Therapy. Nucleic Acids|August 7, 2023
<i>VWA3A</i>-derived ependyma promoter drives increased therapeutic protein secretion into the CSFEllie M Carrell, Yong Hong Chen, Paul T Ranum, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Opinion in Genetics & Development|April 5, 2017
Myotonic dystrophy: approach to therapyCharles A Thornton, Eric Wang, Ellie M Carrell
Annals of Neurology|August 29, 2025
Co-Opting MBNL-Dependent Alternative Splicing Cassette Exons to Control Gene Therapy in Myotonic DystrophySamuel T Carrell, Ellie M Carrell, Ryan Giovenco, et al.
Molecular Therapy. Methods & Clinical Development|May 16, 2022
Combined overexpression of ATXN1L and mutant ATXN1 knockdown by AAV rescue motor phenotypes and gene signatures in SCA1 miceEllie M Carrell, Megan S Keiser, Ashley B Robbins, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 3, 2016
Orai1 enhances muscle endurance by promoting fatigue-resistant type I fiber content but not through acute store-operated Ca2+ entryEllie M Carrell, Aundrea R Coppola, Helen J McBride, et al.
Nature Communications|November 19, 2013
Orai1-dependent calcium entry promotes skeletal muscle growth and limits fatigueLan Wei-Lapierre, Ellie M Carrell, Simona Boncompagni, et al.
Molecular Therapy. Nucleic Acids|September 24, 2024
Cas9 editing of <i>ATXN1</i> in a spinocerebellar ataxia type 1 mice and human iPSC-derived neuronsKelly J Fagan, Guillem Chillon, Ellie M Carrell, et al.
Molecular Therapy. Nucleic Acids|July 9, 2024
Temporal restriction of Cas9 expression improves CRISPR-mediated deletion efficacy and fidelityJesse A Weber, Jonathan F Lang, Ellie M Carrell, et al.
Plos One|November 16, 2012
Allele-specific gene silencing in two mouse models of autosomal dominant skeletal myopathyRyan E Loy, John D Lueck, Mohammed A Mostajo-Radji, et al.
Human Molecular Genetics|August 15, 2016
Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in miceSamuel T Carrell, Ellie M Carrell, David Auerbach, et al.
Molecular Therapy. Nucleic Acids|August 7, 2023
<i>VWA3A</i>-derived ependyma promoter drives increased therapeutic protein secretion into the CSFEllie M Carrell, Yong Hong Chen, Paul T Ranum, et al.
Pageof 2